Lexaria Bioscience Corp. (LEXX) has released an update.
Lexaria Bioscience Corp. has initiated a new research program in collaboration with the National Research Council of Canada to investigate the molecular characteristics and performance of its DehydraTECH technology when used with the GLP-1 drug, semaglutide. The study aims to understand how DehydraTECH-processed semaglutide behaves in simulated gastric fluid, which could lead to improved drug formulations. Early testing has already shown promising results, including higher peak blood levels and better blood sugar control with fewer adverse events compared to unprocessed drugs.
For further insights into LEXX stock, check out TipRanks’ Stock Analysis page.
